Sequenta, Inc., a South San Francisco, CA-based biotechnology company, completed a $20m Series C financing.
The round was led by Foresite Capital Management, with participation from existing investors MDV and Index Ventures. In conjunction with the closing, Jim Tananbaum, managing director of Foresite Capital, joined Sequenta’s Board of Directors.
Led by Tom Willis, CEO, the company is dedicated to improving patient care in diseases mediated by immune cells through measurements of lymphocyte. It recently launched its ClonoSIGHT test, for the detection of residual cancer cells in marrow or blood.
Sequenta now intends to use the funds for commercial scale up and clinical validation of the test.